Clinical Trial

Serratus Posterior Superior Intercostal Plane Block for Arthroscopic Shoulder Surgery

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 4, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Postoperative pain is a significant problem in patients undergoing arthroscopic shoulder surgery. This situation disrupts the patient's comfort and affects the functional outcome after surgery by preventing early rehabilitation. Various methods are used for postoperative pain control. Intravenous opioid agents are one of the most commonly used analgesic techniques. However, opioids can cause undesirable side effects such as respiratory depression, sedation, constipation, allergic reactions, nausea, and vomiting. Therefore, alternative techniques are needed to reduce opioid use. Serratus posterior superior interfascial plane block (SPSIPB) is a novel interfascial plane block described by Tulgar et al in 2023. It is based on injection into the serratus posterior superior muscle at the level of the 2nd or 3rd rib. This block provides analgesia in cases such as interscapular pain, chronic myofascial pain syndromes, scapulocostal syndrome, and shoulder pain. It has been reported that SPSIPB provides effective shoulder analgesia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-04; most recent amendment 2025-07-01.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06866054
Lead Sponsor Kahramanmaras Sutcu Imam University
Conditions Shoulder Pain, Shoulder Injuries
Enrollment 50 participants
Start Date 2025-04-10
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-04